Pharma and Biotech
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-24 | 157.10 | 7.95 | (1.00)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-25 | 170.60 | 16.35 | 1.00p | 35.6 | n/a | n/a | n/a | 0.0% |
30-Sep-26 | 191.75 | 24.15 | 1.70p | 20.9 | 0.3 | +70% | n/a | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
Current | 1 week ago | 1 month ago | 3 months ago | 6 months ago | 1 year ago | |
---|---|---|---|---|---|---|
Revenue (£m) | ||||||
30-Sep-2025 | 171 | 171 | 171 | 190 | 201 | 215 |
30-Sep-2026 | 192 | 192 | 192 | 213 | 225 | n/a |
Earnings | ||||||
30-Sep-2025 | 1.00p | 1.00p | 1.00p | 1.00p | 0.25p | 1.10p |
30-Sep-2026 | 1.70p | 1.70p | 1.70p | 1.70p | 1.70p | n/a |
Dividend | ||||||
30-Sep-2025 | n/a | n/a | n/a | n/a | n/a | n/a |
30-Sep-2026 | n/a | n/a | n/a | n/a | n/a | n/a |
Recommendations | ||||||
Strong Buy | 0 | 0 | 0 | 0 | 0 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Neutral | 1 | 1 | 1 | 1 | 1 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Brokers | 2 | 2 | 2 | 2 | 2 | 4 |
Average Rec | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 | 9.38 |
Find out about IFRS and how this affects the financial infomation for all UK companies.
Currency | UK Pounds |
Share Price | 35.60p |
Change Today | -3.40p |
% Change | -8.72 % |
52 Week High | 48.00 |
52 Week Low | 34.00 |
Volume | 118,205 |
Shares Issued | 739.79m |
Market Cap | £263.37m |
Beta | 0.48 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
13:45 | 3 @ 35.64p |
12:40 | 44 @ 36.00p |
11:41 | 5,682 @ 36.00p |
11:41 | 6,318 @ 36.00p |
11:38 | 7,236 @ 35.61p |
Chair | Peter George |
CFO | Septima Maguire |
CEO | Trond Williksen |
You are here: research